Botulinum toxin for the management of bruxism: an overview of reviews protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
10 Oct 2024
Historique:
medline: 11 10 2024
pubmed: 11 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

Bruxism is characterised by a repetitive activity in the masticatory muscles that involves teeth clenching or grinding and/or forceful mandibular movements. Its management is typically initiated when individuals start experiencing the adverse effects of the condition. One of the available intervention forms is the administration of botulinum toxin type A (BoNT-A). Numerous systematic reviews have addressed the use of BoNT-A to manage bruxism; however, the results are controversial. The current overview aims to determine BoNT-A's effectiveness for managing bruxism in relation to placebo, the absence of treatment or alternative interventions in the adult population. This study will include systematic reviews (SRs), with or without meta-analysis, aiming to evaluate the efficacy of BoNT-A for bruxism in adults. A broad literature search will be carried out on Cochrane Library, EMBASE, LILACS, Livivo, PubMed/MEDLINE, Scopus, Web of Science and the grey literature. Experts in the topic and reference lists of included SRs will also be consulted. The study selection will be conducted in two phases by two independent reviewers. Data collection will be performed by one author and cross-checked by another. The methodological quality of included SRs will be evaluated using AMSTAR-II. A narrative synthesis will be employed as the formal method to combine individual study data. The overlap across studies will be quantified by the corrected covered area and illustrated by the Graphical Representation of Overlap for Overviews. This overview does not require ethics approval, as it uses secondary data from previously published studies. The results will be disseminated through the publication in a high-impact journal. DOI: 10.17605/OSF.IO/RB45T.

Identifiants

pubmed: 39389600
pii: bmjopen-2023-082861
doi: 10.1136/bmjopen-2023-082861
doi:

Substances chimiques

Botulinum Toxins, Type A EC 3.4.24.69
Neuromuscular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e082861

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Manuella Salm Coelho (MS)

Department of Dentistry, University of Santa Catarina, Florianópolis, Brazil.

Júlia Meller Dias de Oliveira (JMD)

Department of Dentistry, University of Santa Catarina, Florianópolis, Brazil.

Helena Polmann (H)

Federal University of Santa Catarina, Florianopolis, Brazil.

Patrícia Pauletto (P)

Facultad de Odontología, Universidad de Las Americas, Quito, Ecuador patricia.pauletto@udla.edu.ec.

Cristine Miron Stefani (CM)

Department of Dentistry, University of Brasilia, Brasilia, Federal District, Brazil.

Lara Catarine De Luca Maciel (LC)

Queen Mary University of London, London, UK.

Graziela De Luca Canto (G)

Department of Dentistry, University of Santa Catarina, Florianópolis, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH